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04W". This study wa designed to evaluate more closely
the true bWmpltd costs of elective revascularisadon by direr .
tional coronary athuetomy and hntracoronary stealing and to
compare these co * with those of the traditional revacularlratlan
alternatives (i.e ., conventional balloon angioplasty and coronary
adery bypas MWO
Previous studies have suggested that total hospital
chwiles. hr directional coronary atbereclonly or iatracoronary
denting are slgnlficatly higher than those for conventional an.
gisplesh. However, hospital charges do not secondly reflect
true economic costs, and their use may provide misleading data
with regard to cost-effectiveness.
Me***
. We analyzed in-hosplt l charges from the Itemized
hospital: accounts of 300 patients tmdergolag elective angioplasty,
directional atherectomy, Palwas-Schatz coronary denting or by.
pass surgery between January 1, 1998 and Dumber 31, 1991 .
Cods were then derived by adjusting Itemized patient accounts for
d paetmaat-spedfic costlcharge ratios . Gaitetezallan laboratory
cots were based on actual resource consumption, and daily room
costs were adjusted for the intensity of nursing services provided .
RaWls, Length. of hospital slay was similar (br atherectomy
(23 * 1.5 dap) and conventional angiopbuty (2 .6 t 1.7 days)
Despite rapid technologic advances over the past 15 years,
percutaneous coronary angioplasty remains limited by sev-
eral problems, including abrupt vessel closure (1-3) and late
restenosis (4-8) . In an effort to overcome these limitations,
several new mechanical revascularization techniques have
been developed, including directional coronary atherectomy
(9) and intracoronary scenting (10-12). Although neither
atherectomy nor stenting has completely eliminated the
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but significantly longer for denting (S .S * 2.6 days, p < 0.05).
Total costs were also significantly higher for coronary stealing
($7,878 * $3,278, median $6,699, p < 0,05) than for angioplasty
($5,396 f $2,829, median $4,753) or atherectomy ($5,726 ±
$2,716, median $4,986) . &Iowuver, length of stay, resource con .
sumption (laboratory ad radtologic testing, drugs, blood prod .
ucts, for example) and total costs for bypass surgery were still
greater than for any of the percutaneous interventional proce-
dures.
Conciwsams . In contrast to previous studies utilizing only
hospital charges, the in-hospital costs of angioplasty and direr.
tional coronary atherectomy were similar . Although the cost of
coronary stenting was approximately $2,500 higher than that of
conventional angioplasty, the magnitude of this difference was
smaller than the $6,300 increment previously suggested on the
basis of analysis of hospital charges. These findings reflect the
inherent discrepancies between cost-based and charge-based
methodologies and may have Important implications for future
studies evaluating the relative cod-effectiveness of newer coronary
Interventions .
rJ Am Cell Cahdiol 1993,22:1052 .9)
drawbacks of conventional angioplasty, in our experience
both techniques have appeared to provide more favorable
immediate results and potentially less restenosis for certain
unfavorable lesion types (13-16) .
Previous studies, however, have suggested that hospital
charges for atherectomy or coronary stenting may be 30% to
100% higher than those for conventional angioplasty (17).
This observation has raised questions as to whether such
interventions could ever be cost-effective and has added to
skepticism about the role that these new devices might play
in interventional cardiology (18-20). It is well recognized,
however, that hospital charges may not reflect the true
economic costs of a procedure (21-24). To determine the
potential cost-effectiveness of these new techniques, it is
necessary to start with a careful assessment of their actual
costs and those of potential alternative therapies . We there-
fore undertook the present study to provide a better under-
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COSTS AND CHARGES
OF ELECTIVE REVASCULARIZATION
standing of the true costs of directional coronary atherec-
tomy and intracoronary stenting compared with those of the
alternative therapies of conventional balloon angioplasty and
coronary artery bypass surgery .
Methods
Patients. Between January 1 . 1990 and December 31,
1991, 1,562 percutaneous coronary interventions and 1,088
isolated coronary artery bypass operations were performed
at Boston's Beth Israel Hospital . Of the percutaneous coro-
nary interventions, 1,194 patients (76%) were treated with
conventional angioplasty, 140 (9%) with directional coronary
atherectomy and 228 (15%) with Palmaz-Schatz coronary
stenting. Most of the patients treated with either new tech-
nique were considered to have a higher than average prob-
ability of an adverse short- or long-term outcome with
conventional angioplasty because of lesion eccentricity,
ulceration, ostial location or previous restenosis .
To minimize selection bias, analysis of the stent, atherec-
tomy or angioplasty procedures was restricted to patients
with New York Heart Association functional class 11 or 11I
angina who underwent elective revascularization of a single
major coronary artery or saphenous vein graft . In general,
such patients were admitted to the hospital on the day of
their revascularization procedure . Patients with multivessel
coronary disease or previous bypass surgery were eligible
only if the planned coronary intervention was restricted to a
single vessel . Patients with ongoing acute myocardial infarc-
tion or unstable angina who required hospitalization before
the procedure were excluded .
Patients undergoing bypass surgery were included if they
had functional class 11 or III angina and were admitted elec-
tively for the purpose of isolated bypass surgery . These pa-
tients were generally admitted to the hospital on the day before
their planned procedure . Because of the small number of
patients undergoing single-vessel bypass surgery during the
study period, and because most of the costs of bypass surgery
(operating room time, anesthesia, room and nursing costs,
drugs, among others) are relatively independent of the number
of bypassed vessels (25,26), elective single-vessel and multi-
vessel bypass operations were included.
Study group . The final study group included all eligible
patients who underwent attempted atherectomy or coronary
stent placement during the 2-year period . To study a similar
number of patients in the angioplasty and bypass surgery
groups, 6 months was chosen at random from the 2-year
study period . Any eligible patient who underwent angio-
plasty or bypass surgery during those 6 months was included
in the analysis .
Interventional procedures. During the study period, post-
procedure patient management was performed according to
standardized protocols designed to optimize patient outcome
for each procedure, without specific attention to hospital
costs. Angioplasty was performed according to standard
methods. After successful angioplasty, patients were admit-
COHEN ET A1
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led to a specialized monitoring unit overnight. Arterial
sheaths (7F or 8F) were generally removed the following
morning, and patients remained at bed rest for an additional
12 to 24 h . Patients in whom a significant arterial dissection
was present after angioplasty generally received an addi-
tional 24 to 48 h of intravenous heparin after sheath removal,
before hospital discharge . Directional atherectomy and
Palmaz-Schatz coronary stent placement were performed
according to protocols that we have previously described
(13,14,27) .
Procedural success was defined as the successful reduc-
tion of the target vessel stenosis to <50% without major
in-hospital ischemic complications (death, Q wave myocar-
dial infarction or unstable angina requiring repeat dilation or
bypass surgery) . Major vascular complications were defined
as any vascular complication (pseudoaneurysm, arterio-
venous fistula, hematoma) that resulted in either transfusion
or vascular repair .
Determination of hospital costs. Charges . Hospital
charges were determined from each patient's itemized hos-
pital account . All charges incurred during the admission
were considered related to the procedure and were included
in the analysis. Because our institution does not routinely
charge patients for individual balloon catheters or devices,
catheterization laboratory procedural charges were assessed
in two alternative ways . In Method l, our standard proce-
dural charge of $5,180 for a single-device interventional
procedure or $5,800 for a multiple-device interventional
procedure was used . In Method 2, a baseline procedure
charge ($4,580) was augmented by the total manufacturers'
charge to the hospital for all balloons and devices used (at
$695/balloon and $1,0001atherectomy device or stent) . All
charges and costs were expressed in terms of 1991 dollars .
Charges incurred in 1990 were adjusted to 1991 levels on the
basis of the medical care component of the Consumer Price
Index. Additional charges incurred by patients who required
readmission within 2 weeks of discharge for treatment of a
complication of the original procedure (e .g ., vascular com-
plication, wound infection) were also included .
Costs . True economic costs are best determined as the
marginal costs of all resources consumed in producing a
good or service . Determination of true hospital costs there-
fore requires detailed analysis of each patient's resource
consumption (21) .
Cardiac catheterization laboratory utilization and costs .
Cardiac catheterization laboratory costs were estimated as
the costs of all supplies and personnel utilized in each
procedure . Resource utilization-including angioplasty bal-
loons, devices (atherectomy catheters and scents), guiding
catheters, guide wires and contrast dye-was recorded for
each procedure, and the cost of each item was determined
using actual manufacturers' charges to the hospital during
fiscal year 1991 . Additional equipment costs, laboratory
room costs (including overhead and depreciation) and per-
sonnel costs were estimated on the basis of an average cost
per procedure and adjusted for actual
procedure duration .
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Hospital room and nursing costs
. The major component
of hospital room cost in this study was personnellnursing
cost. To adjust for the wide variation in nursing service
utilization (even among patients on the same nursing unit), a
"mining intensity factor" was utilized to represent the
intensity
; of nursing services required by each patient for
each hospital day, relative to the other patients on the same
nursing unit. This factor was calculated as the ratio of the
patient's "classification score" (a measure of nursing acuity
that has been shown to correlate closely with nursing re-
source utilization) (28) to the mean patient classification
score for all patient-days on that specific unit during the
same fiscal year. Average cost per day on each unit was
obtained from hospital accounting data and included person-
nel costs, other direct costs and the portion of hospital
overhead allocated to the unit by the accounting department .
Daily room costs were then obtained by multiplying the
average cost per day on the unit by the nursing intensity
factor for each patient-day . The nursing intensity adjustment
was applied to personnel costs and direct room costs only .
Patient
.,days with missing classification scores were assigned
a score equivalent to the mean classification score of all
patients on that unit
.
Other hospital costs . The costs of all other hospital
services (including laboratory and radiologic testing, drugs
and intravenous fluids, blood transfusions and operating
room and anesthesia services) were determined on the basis
of the number of units of each service utilized . The cost of
each unit of service was estimated as the charge per unit of
service, multiplied by the specific costlcharge ratio for the
hospital department providing the service .
StlWal ugly b, All data are reported as mean value t
SD. Selected cost data are also reported as median values
with 25th a d 75th percentiles . Discrete variables were
compared by chi-square analysis or the Fisher exact test
where appropriate, Continuous variables were compared by
analysis of variance, using the Bonkrroni correction for
MW ti* comparisons . Cost data and other nonparametric
variables were compared by the Wilcoxon rank-sum test and
the Kruskal-Wallis test. All p values are two-tailed, and a
level of p < 0.05 was considered statistically significant .
Table 1 . Patient Characteristics
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*p < 0
.05 compared with angioplasty, tp < 0.05 compared with atherec
.
tomy, Ip < 0.0S compared with stenting. §Verse! treated not listed for
coronary artery bypass grafting (CABO) because most patients underwent
multivessel revascularization . Values presented are mean value t SD or
number (%) . LAD - left anterior descending coronary artery ; LCx = left
circumflex coronary artery ; PTCA
: percutaneas transtuminal coronary
angioplasty ; RCA - right coronary artery ; SVG a saphenous vein graft .
artery revascularization than the angioplasty or stent group .
Patients treated with coronary stenting were more likely to
be undergoing treatment of a saphenous vein graft stenosis .
These baseline differences reflect the somewhat different
indications used for directional atherectomy and coronary
scenting during the study period .
Procedural outcome was generally similar among the
three percutaneous interventions (Table 2) . The slightly
lower rate of procedural success for angioplasty was due
mainly to failure to cross the lesion in 8 of 14 patients with
total occlusions, an indication that accounted for 15% of the
angioplasty group. Four patients who underwent attempted
atherectomy could not be so treated owing to inability to
deliver the atherectomy device across the stenosis, but each
then underwent successful balloon angioplasty as part of the
same procedure. They are considered part of the atherec-
tomy group for the purposes of this study. As expected,
because of the need for uninterrupted anticoagulation ther-
apy, the rate of vascular complications requiring either
PTCA
(a = 113)
Atherectomy
(n = 34)
Scenting
(n = 64)
CABG
(a = 89)
Age(yr) 59 :t 11 59 ± 10 57 ± 12 63 19*4
Male 92(81) 29(85) 54(94) 75(84)
Multivessel disease 43(38) 7(21) 24(38) 84 (95)*f#
Multilesion dilation 4(4) 1(3) 3(5)
Vessel treated
LAD 4903) 2306)21 (62M
LCx 2209) 4 (12) 904)
RCA 41(36) 4 (12)*7 17 (27)
SVG 1(1) 4(121 14 (22)*t
Left main 0 (0) 1(3) I (2)
Results
To* 2. Procedural Outcome and In-Hospital Complications
PICA Atherectomy Stenting
Study group, The study group comprised 300 patients
34000%) 63(98%)Procedural success 98 (87%)*t
who underwent attempted elective angioplasty (113 pa-
tients), directional coronary atherectomy (34 patients),
Failure
4 (12%4 OW)Failure to cross or dilate 11(10%)
Palmaz-Schatz coronary stenting (64 patients) or coronary Emergency CABG 10%) 0(0%) I (2)
artery bypass surgery (89 patients) between January 1
. IM
Death 1(1%) 001%) 0(0%)
and December 31, 1991 . Table I displays the baseline
demographic and angiographic characteristics of the total
Restudy for pain or ischemia
Vascular complications
Surgical repair
4(3%)
1(1 )
1(3%)
0M)
1(2%)
6 (9%)*8
group
. Although there were no significant demographic
Bleedlhematoma 0(0%) 0(0%) 2(3%)
differences among the three interventional procedures, pa-
tieft in the bypass surgery group were slightly older than
those in the other treatment groups, and the atherectomy
group had a higher frequency of left anterior descending
*p < 0
.05 compared with atherectomy . t p
< 0
.05 compared with stealing .
f These four patients subsequently underwent successful angioplasty during
the same procedure and are therefore included in the procedural successes .
Sp < 0.05 compared with angioplasty . Abbreviations as in Table 1 .
JACC Vol . 22, No. 4
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Table 3 . Catheterization Laboratory Resource Utilization and Cost by Procedure
12,211, 2 .707 , 3,411)
'p < 0 .05 compared with angioplasty . t p < 0 .05 compared with atherectomy, tp < 0.05 compared with stenting .
values presented are mean value ± SD,, values in parentheses represent the 25th . 50th and 75th percentiles .
respectively . PTCA
e
perenlaneous trunsluminal coronary angioplasly .
transfusion or surgical repair was significantly higher in the
patients treated with coronary stenting .
Catheterization laboratory resource utilization and costs .
The pattern of resource consumption in the catheterization
laboratory differed significantly among the three interven-
tional procedures (Table 3) . Compared with conventional
angioplasty . atherectomy had a similar procedure duration
and higher average contrast utilization but required 41%
fewer angioplasty balloons/procedure (in addition to the
atherectomy device itself) . In contrast, coronary stenting
required on average 20% less procedure time than either
angioplasty or atherectomy but conferred no associated
reduction in adjunctive balloon utilization compared with
angioplasty, given the frequent use of adjunctive balloon
dilation before and after stent placement .
Examination of the catheterization laboratory resource
costs associated with each procedure demonstrates that the
largest single component of procedural cost was the cost of
the devices (angioplasty balloons, atherectomy catheters
and stents). Thus, the procedural costs of atherectomy were
significantly higher than those of conventional angioplasty .
The catheterization laboratory costs for stenting were even
higher than those for atherectomy owing to the more fre-
quent adjunctive use of conventional angioplasty balloons
(1 .7 ± 0 .7 balloons/stent procedure vs . 1 .0 t 1 .6 balloons/
atherectomy procedure, p < 0.05). The minor cost savings in
personnel and room/overhead costs for stenting (compared
with costs for angioplasty or atherectomy) did not substan-
tially offset these markedly higher balloon and device costs .
Inpatient resource utilization and costs . The mean length
of hospital stay, number of intensive care unit days and
nursing intensity were similar for patients treated with
conventional angioplasty or atherectomy (Table 4). As a
result, there was no significant difference in overall cost
between these two procedures . In contrast, coronary stent-
0,599 . 2 .856.3,718)
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ing resulted in a significantly longer hospital stay than
either angioplasty or atherectomy, leading to higher hospital
costs in most resource categories. The overall hospital cost
of stenting ($7,878 t $3,270, median $6,699) was thus
significantly higher than that of either angioplasty ($5,396 ±
$2,829, median $4,753) or atherectomy ($5,726 ± $2,716,
median $4,986). Not surprisingly, the overall cost of
bypass surgery ($20,937 t $6,048, median $19,153) was
much greater than the cost of any of the interventional
procedures .
As measured by the patient classification score, the
relative intensity of nursing care decreased significantly for
all percutaneous procedures after hospital day 2 Wig . 1) .
Because length of stay was significantly longer for stenting
than for either angioplasty or atherectomy, the impact of this
reduction in nursing intensity beyond day 2 on hospital costs
was most pronounced for patients with stenting . Averaged
over the entire hospital stay, the mean nursing intensity (per
hospital day) was thus significantly lower for stenting (1 .1 ±
0.9 arbitrary units) than for angioplasty or atherectomy
(1 .6 ± 0.9 and 1 .8 ± 1 .1 arbitrary units, respectively) . Even
though total room costs were greater, the average daily
room cost for patients with stenting ($494 ± $193) was
significantly lower than that for patients with either angio-
plasty or atherectomy ($619 ± $232 and $632 t $242,
respectively. p < 0 .05) .
Influence of cost accounting method on overall costs . The
use of hospital charges (rather than adjusted costs) did not
alter the general conclusions of the analysis . Our own
(Method 1) hospital charges were similar for angioplasty
($8,639 ± $3,885, median $8,005) and atherectomy ($8,391
t
$2,299, median $8,032) but were significantly higher for
stenting ($12,670 ± $5,247, median $10,992, p < 0.05 com-
pared with charges for angioplasty and atherectomy) or
bypass surgery ($27,739 ± $7,051, median $25,907, p < 0
.05
FTCA Alherectomy Stealing
Length of procedure (min) 83 ± 35 85 ± 38 66 ± 22't
Contrast dye used (ml) 208 ± 86 2 .57 ± 76't 204 ± 67
Stent or atherectom} devices (no.) 0 ± 0 1 .0 ± 0.2 1 .1 ± 0.2
Conventional balloons (no.) 1 .7 ± 0.8 1.0±1.6't 1 .7±0.7
Cost ($)
Balloons/devices 1 .169 ± 567 1 .686 ± 1 .097' 2 .220 ± 582't
(00. 650 . 1 .300) (1 .000. 1,000.2 .350) (1 .675, 2,350, 2,350)
Supplies 700 ± 43 724 ± 38' 698 ± 33
(671, 686. 721) 1695 . 721 . 746) (672, 691 . 712)
Roomloverhead 890 ± 374 910 ± 409
707 ± 239't
(645, 796. 1,076) (678, 801, 968) (559. 645 . 780)
Personnel 181 ± 52 184 ± 57 156 ± 33't
(147, 168, 2071 (152, 169. 192) (135 . 147, 166)
Total(.(wt 1.61 2,938 ± 859 3,451 ± 1,501' 3,781 ± 745't
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Table 4.
Inpatient Costs and Resource Utilization
(3,997, 4.733, 5 .663)
"Length of hospital stay, intensive care unit (ICU) days, total nursing intensity and all costs (except catheterization laboratory [Cath lab] costs) were
significantly greater for bypass surgery than for any of the interventional procedures, but symbols have been milled for
clarity . t
p
< 0.05 compared with
angloplasty . tp < 0.05 compared with atherectomy . §Catheterization laboratory costs are slightly different from those in Table 3 owing to costs of repeat
procedures in same patients. Values presented are mean value t SD ; values in parentheses represent the 25th, 50th and 75th percentiles . OR = operating room;
other abbreviations as in Table 1 .
compared with all interventional procedures), Parallel differ-
ences were apparent in the comparison using individual
device charges (Method 2) as well .
The method of cost accounting (charge based vs. cost
I
(4.184. 4,986, 5,709) (6,247, 6.699, 8,018)
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(17,420, 19.153 . 21,828)
based) did not appreciably affect the incremental cost of
atherectomy relative to angioplasty (-$200 to +$300, Table
5). On the other hand, the method of cost accounting had a
profound effect on the incremental cost of stenting relative to
Figure 1
. Daily nursing intensity factor (measured
relative to that of other patients on the unit) for
patients undergoing elective angioplasty, atherec-
tomy or coronary stenting . There was a significant
(p < 0
.001) decrease in nursing intensity for all
interventional procedures comparing hospital days
I and 2 (2.0 ± 1.0 arbitrary units) with all other
days (0.9 ± 0.5 arbitrary units). The numbers
below the graph represent the number of nursing
classification scores available and the total number
of patients hospitalized on each day . Only 24% of
patients had nursing classification scores recorded
on hospital day I because few patients were admit-
ted to the nursing unit by 10 AM, when the scores
were tabulated .
PTCA Atherectomy Stenting
CABG*
Days of hospital stay
2
.6 *_ 1 .7 2.3 t 1.5
5 .5 t 2.6tt 9 .3 ± 3 .6
Days in ICU
0.2 ± 0.6
0.1 t 0.7 0.3 t 1.1 2 .5 ± 2 .0
Mean daily nursing intensity
(arbitrary units)
1 .6 ± 0.9 1
.8 ± 1
.1
1 .1 t 0.9t4 1 .0 t 0 .5t*
Total nursing intensity
(arbitrary units)
Costs (S
.1
3 .4 ± 1 .9
3.3 ± 2.2 5 .5 ± 2.6t1 9 .5 ± 3 .8
F!ncedurai
3,167 t 1,191
3,567 ± 1,480 4,122 t 1,2751 5,610 ± 1,042
(2,324.2 .946.3
.682) (2.6 93,1094,063) (3,054, 3,318, 3,872) (5,131, 5,613, 6,174)
Cath labs 3,0822959 3,567 ± 1,480t
3,847 t 746t
0
(2,324
.2,933, 3 .682) (2.629,3,1104,063) (3.318
.3,847, 4,081) (0.0,0)
OR
85 t 637 0
275 t 849 5
.610 t 1 .042
(0.010)
(0, 0.0) (01010)
(5 .131, 5,613, 6,174)
Room/nursing
1,585 t 1,174
1,490 ± 1,284 2,561 :t 1,624t$ 8,760 t 3,549
(1 .006.1 .300.1 .750)
(785.1,17785 )
(1,719,1,966.2,765)
(6,773, 7 .544, 9,439)
Laboratory
136 t 120 147 t 159 341 t 324t* 1 .013 t 530
(90,106, 132) (90 .105,140) (196, 240, 312) 1764, 882, 1,093)
Blood bank
104 t 210 89 t 100 159 :t 316 428 t 450
(50.100,102) (50.51,100)
(50, 51 .100) 1209, 318, 455)
Pharmacy 161 t 165
129 t 106 358 t 139t$ 852 t 474
(97,132, 160) (79, 100, 151) (282, 326, 392) (633, 790, 976)
Radiology
81 t 82 83 t 77 167 ± 20014 689 t 407
(77,80, 87) (77, 80,87) (80,80,173) (438, 560, 708)
Miscellaneous 161 t 394 221 ± 136 171 ± 490 3,503 ± 870
(77, 101, 122) (103.251 . 319) (53, 96, 121) (2,980, 3,279, 3,884)
Total cost (a) 5,396 t 2,829 5 .726 ± 2,716 7.878 *_ 3,270t$ 20,937 ± 6.048
HMPNONY
NOORV 21/113 851101 28134 10114 7110 12/17
M _ __ .. aq 8134 23121= 9110 313 011 4/4
am
22181
54164 54161
41151
=136 32139
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angioplasty, Hospital charges for stenting averaged $4,000 to
$4,700 higher than those for angioplasty, whereas resource-
based cost accounting showed that. stenting had an incre-
mental cost of only $2,482 compared with that of conven-
tional angioplasty. However, the cost of bypass surgery
remained significantly higher than that of angiopiasty,
atherectomy or stenting regardless of which cost accounting
method was used .
Subgroup analysis . Although there were several baseline
differences between the patients treated with conventional
angioplasty and the patients treated with new devices, stratified
analysis did not alter the results of the overall cost analysis .
Even after stratification by gender, age (<60 vs . ?60 years) or
vessel treated, the costs of angioplasty and atherectomy re-
mained similar and significantly lower than the cost of stenting .
Furthermore, exclusion of the I I patients with conventional
angioplasty with a procedural failure (which in 8 cases was due
to inability to cross a total occlusion) did not affect the results
of the analysis because the length of stay (2 .7 t 1 .5 days) and
total hospital cost ($5,291 ± $2,350, median $4,773) of patients
with successful angioplasty were similar to those of the overall
angioplasty group.
The cost of stenting was significantly greater in the
subgroup of patients who had a vascular complication .
Compared with the other patients with stenting, patients
with vascular complications had a longer hospital stay
(10.0 ± 4.6 vs . 4 .6 ± 1 .3 days), higher costs for laboratory
testing ($1,789 ± $1,101 vs . $821 # $75) and blood bank
services ($1,035 ± $955 vs . $123 ± $174) and higher total
hospital costs ($12,393 ± $3,338 vs . $7,233 ± $2.727, p <
0.001 for all comparisons). Nevertheless, even among pa-
tients without vascular complications, the total cost of
stenting remained significantly greater than those of conven-
tional angioplasty ($7,233 ± $2,727 [median $6,594] vs .
$5,396 ± $2,829 [median $4,753], p < 0 .001) .
Discussion
In this study, we examined charges, resource consump-
tion and the actual costs of initial hospital stay for 30D patients
undergoing elective revascularization by angioplasty, direct
COHEN ET AL
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Table 5. Effect of Cost Accounting Method on the Costs of Atherectomy, Coronary Sienting and
Bypass Surgery Compared With That of Angioplasty
A = difference between the overall cost of each procedure and the cost of angioplasty (i .e . . the incremental
cost
compared with the cost of angioplasty). Method I charges = actual hospital charges, including standard catheter-
ization laboratory charges ($5,180 per single-device interventional procedure and
$5,800 per multiple-device
interventional procedure. Method 2 charges = based on a baseline procedure charge
plus an additional charge for
each balloon, scent or atherectomy device used. Abbreviations as in Table 1 .
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tional atherectomy, halmaz-Schatz coronary stenting or by-
pass surgery. As expected, the total in-hospital costs were two
to three times higher for bypass surgery than for any of the
percutaneous interventional procedures. Among percutaneous
interventional procedures, detailed resource accounting dem-
onstrated that atherectomy and stenting each had slightly
higher catheterization laboratory costs than those of conven-
tional angioplasty . Although there was no -dignificant difference
between the total cost of atherectomy or a : tgioplasty, coronary
stenting did entail a longer hospital stay and increased utiliza-
tion of resources (including laboratory testing, radiology and
pharmacy services) . As a result, total hospital costs for stenting
were 35% to 45% higher than for the other interventional
procedures, although the incremental cost of coronary stenting
compared with that of angioplasty ($2.400/procedure) remained
substantially smaller than that of bypass surgery ($15,0001
procedure) .
Comparison with previous studies. In the only previous
study to assess the economic impact of these three percuta-
neous revascularization techniques, Dick et al . (17) found
that hospital charges were significantly higher for directional
atherectomy than for conventional angiopiasty and higher
still for coronary stenting. Using hospital charges, they
suggested that the "cost" of atherectomy was 34% higher
(an increment of $2,109/procedure) and that the "cost" of
stenting was 103% higher (an increment of $6,354/procedure)
than that of conventional angioplasty . Even after adjustment
for the 0.76 costlcharge ratio in their study, the absolute cost
increase over angioplasty of $1,600 for atherectomy and
$4,800 for stenting would be significantly higher than those
determined by the current study .
Several factors may account for the apparent differences
between these two studies. First, the mean length of stay for
elective angioplasty in the study by Dick et al . (17) was only
1 .5 days (compared with 2.6 days in the current study)
.
Although most recent studies suggest a 4- to b-day length of
stay for angioplasty (22,29), the unusually short length of
stay for angioplasty in the study by Dick et al
. would have
tended to exaggerate any difference in costs between angio-
plasty and the other procedures . Because the power of our
study to detect a true difference of $1,600 in hospital cost
Charges: Method I Charges
: Method 2 Costs
Total A (k) Total
A t%)
Total
A I`h)
PICA $8,639 - $8,703
$5 .396 -
Alherectomy $8,391 -$248(-21 .915
S2120) $5,726 $330(6)
Stent
$12,670
$4,031(47) $13,370
S4.66704) $7,878 S2,48206)
CABG $27,739
$19,100 (221) $27.739 $19.036 (219) $20,937
$15.541(288)
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between angioplasty and atherectomy was 85%, it would be
unlikely that we would have failed to detect such a cost
difference had it existed in our study group .
Another critical difference between the two studies is in
the distinction between costs and charges . Although Dick
et al . used hospital charges as a surrogate for costs, it is well
recognized that charges may bear little relation to costs and
that true economic costs may differ from accounting cost
estimates (21). These differences explain why previous stud-
ies have demonsmited that the relative "cost" difference
between bypass surgery and angioplasty is highly dependent
on which method is used for cost accounting (22).
Our study used the average costs per unit of service
(including a portion of allocated hospital overhead) to estimate
the economk ros#c of most services, such as laboratory
studies, radiologtc testing and pharmacy supplies . This ac-
counting method assumes that hospital costs are strictly pro-
portional
to the number of procedures performed and may
therefore tend to overestimate the true economic cost (i .e ., the
marginal cost) of providing an additional unit of service . To
minimize that potential error for the two largest components of
hospital cost catheterization laboratory procedures and
nursing-we measured actual resource consumption and based
our estimates on the direct costs of resources consumed . In the
catheterization laboratory, costs were estimated as the actual
cost of resources consumed (balloon catheters, devices, con-
trast dye, nurse and technician salaries, and so forth) . Simi-
larly, the true cost of room and nursing services was estimated
by adjusting the nursing component of room costs for the
relative intensity of nursing services provided .
The importance of measuring costs (rather than charges)
is demonstrated by the striking differences in the estimates
of the incremental costs of stenting compared with those of
angioplasty provided by these two methods (Table 5) . Using
a charge-based methodology, the apparent "cost' of stent-
ing would be $4,000 to $4,700 greater than that of angioplasty
(depending on which method was used to calculate hospital
charges). After adjusting for the cosdcharge ratio and esti-
mating actual catheterization laboratory and nursing costs,
however, the incremental cost of stenting compared with
that of angioplasty was only $2,482 . Of note, the difference
between charges (by Method 2) and true cost is greater for
stenting ($5 .492 :: $2,186) than for either conventional
angioplasty ($3,307 t $1,4W) . kr• atherectomy ($3,189 ±
$793, p < 0.001 for both comparisons) . If hospitals were fully
reimbursed for charges, the average "profit" per procedure
would thus be higher for stenting than for angioplasty or
atherectomy
. However, because most third-party payers
pay the same fixed capitation for stenting as for angioplasty,
the tine "profit" may actually be lower for stenting than for
other interventional procedures .
Dil Deices is rmonrce utilisation. In addition to the dif-
ferences in hospital costs, there were several important
differences in the patterns of resource consumption among
the three percutaneous revascularization techniques. Com-
pared with either angioplasty or atherectomy, coronary
stenting required significantly less catheterization laboratory
procedure time . This finding most likely reflects the techni-
cal ease and excellent immediate results of coronary stenting
(14). Although the technical difficulty (and resulting proce-
dure time) of directional coronary atherectomy is somewhat
greater, the excellent immediate results still allow it to fall
within angioplasty-like procedure times, with less utilization
of adjunctive angioplasty than is required by either conven-
tional angioplasty or stenting.
This analysis of resource utilization and its associated
costs suggests several potential strategies for reducing the
cost of stenting. The increased catheterization laboratory
costs of stenting are due primarily to the frequent use of both
presunt and poststent dilation with conventional angioplasty
balloons, Technical improvements that significantly de-
crease stent profile may decrease the need for predilation,
whereas efforts to use an optimally sized balloon for initial
stent delivery might also decrease cost by reducing the need
for dilation after stenting . The increased hospital cost of
coronary stenting is also related to a longer hospital stay,
which increases room, laboratory and pharmacy costs . Fur-
ther efforts to reduce length of stay after coronary stenting,
either by modification of stent design (e.g., heparin coating)
or by initiation of oral anticoagulant therapy the day before
stent placement, might therefore be warranted.
Study limitations. The major limitation of this study is
that it was a retrospective, observational study rather than a
randomized trial, As a result, there may have been underly-
ing differences in the treatment groups that accounted for the
observed differences in costs and resource utilization . How-
ever, after adjusting for these baseline demographic and
angiographic differences, the particular interventional pro-
cedure performed remained the most important determinant
of in-hospital cost. Given the relatively small number of
atherectomy patients, our study only had a power of 45% to
detect a $1,000 cost difference between atherectomy and
conventional angioplasty. If the results of atherectomy were
no better than those for angioplasty, such a cost difference
might indeed be important. The true cost difference between
atherectomy and angioplasty, however, is unlikely to be as
high as the $1,600 to $2,000 range suggested by previous
studies because our study had an 85% power to detect such
a difference. It is also possible that the high success rate for
atherectomy and the relatively low success rate for angio-
plasty tended to bias our study against finding a cost differ-
ence between these procedures; however, we found no
significant difference in cost, even when the unsuccessful
angioplasty procedures were excluded from the analysis as
potential outliers .
Another limitation is the use of accounting costs (rather
than true economic costs) for many hospital services . By
incorporating a component of hospital overhead into the cost
estimates, accounting cost tends to overestimate the true
economic (i .e ., marginal) costs of each additional procedure
and thus to overestimate differences in procedural costs .
This is because only some components of overhead vary in
JACC Vol . 22, No. 4
October 199.3 :I052-9
	
COSTS AND CHARGES OF ELECTIVE REVASCULARIZATION
proportion to direct service costs, whereas others are fixed
in the short run . We attempted to minimize this potential
error, however, by using measures of actual resource con-
sumption to calculate the direct, variable costs of the two
largest resources: nursing and catheterization laboratory
costs. Finally, we considered only those costs incurred
during the initial hospital stay (and for its immediate com-
plications) . Previous studies have demonstrated that 20%a to
40% of the initial cost savings of angioplasty compared with
bypass surgery are lost during the l,{t year of follow-up
because of procedural failure requiring later bypass surgery
or restenosis requiring repeat angioplasty (30-34) . Compar-
ison of such induced costs is likely to be most practical in the
setting of a randomized trial . We also ignored any indirect
costs due to loss of patient productivity (23,24), which are
likely to be greater for patients undergoing stenting (owing to
the longer hospital stay) or bypass surgery (owing to both the
longer hospital stay and subsequent recuperation) .
Conclusions. In this study of the in-hospital costs of
elective coronary revascularization, we found in contrast to
previous studies of hospital charges, that the costs of
atherectomy and conventional angioplasty are similar. Al-
though the cost of stenting remains significantly higher than
that of either angioplasty or atherectomy, the absolute
difference of $2,400 is much smaller than previously sug-
gested. These findings may have important implications for
the potential cost-effectiveness of atherectomy and coronary
stenting and deserve further attention in future randomized
trials comparing these devices with conventional angioplasty
for specific types of lesions .
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